Introduction: While standard treatment for younger patients with PTCL is chemotherapy and HD consolidation with stem cell rescue, treatment of o lder patients with PTCL is less defined, due to lack of clinical trial data and comorbidities due to ageing. Here we detail our single center outcomes of patients who were 70 years of age or older. Methods: We retrospectively reviewed the clinical characteristics, treatment used and outcomes of patients 70 years of age or older who were treated at Roswell Park Cancer Center for PTCL between 1/1/2001 to 12/31/2021. The patients were divided into three groups, group 1 received single agent therapy, group 2 received multiagent chemotherapy and group 3 received palliative radiation or no therapy. The baseline characteristics were described using descriptive statistics and survival were compared using Kaplan Meier method. Results: Forty elderly T cell lymphoma patients were treated at our center. The median age of whole cohort was 77 years, with 24 males and 16 females. Thirty patients had stage 3/4 disease at the time of diagnosis. The most common diagnosis were ALK -ve ALCL (n=14) and AITL (n=14), while ten patients had PTCL-NOS, and one patient had ALK +ve ALCL and PTCL-TFH each. Seven patients received single agent treatment (G1, n=7), of which six received brentuximab while one received lenalidomide. Twenty nine patients received multiagent treatment (G2, n=29), of which 22 patients received CHOP/CHOEP based therapy, 4 reveived HyperCVAD, and 3 received other chemotherapy treatments. Four patients received no treatment or palliative radiation only (G3,n=4). The patients in G1 were older (median age 85 years), compared to G2 (median age 74 years) and G3 (median age 75 years). The median ECOG of G1, G2 and G3 were 2, 0 and 1 respectively. The ORR of patients in G1 and G2 was 6/7 and 18/29 with CR of 4/7 and 14/24 respectively. Three patients in G2 died due to complications related to induction chemotherapy. Only two patients received autologous transplant after multiagent therapy, none of patients in G1 received an autologous transplant. The median overall survival of patients in G1, G2, and G3 was 25 months, 31 months and 2 months respectively, with no statistically significant difference between G1 and G2 (p=0.63). The median progression free survival of G1 and G2 was 27 months and 14 months (p=0.7). Conclusions: Older patients with T-cell lymphoma can be treated with personalized treatment based on comorbidities and performance status. We found that single agent treatment in selected group of patients produced statistically similar PFS and OS as multiagent treatment.

Citation Format: Muhammad Salman Faisal, Gabrielle Hartman, Francisco Hernandez-Ilizaliturri, Sucharita Sundaram, Pallawi Torka, Paola Ghione. Treatment of elderly patients with Peripheral T-Cell Lymphoma (PTCL): A single institution experience [abstract]. In: Proceedings of the Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application; 2022 Jun 23-26; Boston, MA. Philadelphia (PA): AACR; Blood Cancer Discov 2022;3(5_Suppl):Abstract nr A20.